Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F McDermott

Showing results (51-60 of 666) with videos related to

Pageof 67
Sort By:
Bioscience Reports|June 22, 2017
Effects of microRNA-146a on the proliferation and apoptosis of human osteochondrocytes by targeting TRAF6 through the NF- κB signalling pathwayCamilla West, Michael F McDermott
Genes and Immunity|July 26, 2002
Genetics of type 1 diabetes mellitusF Pociot, M F McDermott
Current Oncology Reports|March 23, 2013
Novel immunotherapies in GU malignanciesAlexandra Drakaki, David F McDermott
The Netherlands Journal of Medicine|October 5, 2001
Hereditary periodic fever syndromesM F McDermott, J Frenkel
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 30, 2018
Progress in Kidney Cancer Outcomes Through Collaboration, Innovation, and DiscoveryDavid F McDermott, Michael Carducci
Expert Opinion on Biological Therapy|August 21, 2018
Ipilimumab in combination with nivolumab for the treatment of renal cell carcinomaXin Gao, David F McDermott
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 21, 2015
Emerging role for novel immunotherapy agents in metastatic renal cell carcinoma: from bench to bedsideMatthew Weinstock, David F McDermott
Current Opinion in Allergy and Clinical Immunology|January 31, 2004
The autoinflammatory syndromesMichael F McDermott, Ivona Aksentijevich
Expert Opinion on Investigational Drugs|December 16, 2014
Nivolumab for the treatment of cancerAnasuya Gunturi, David F McDermott
Current Treatment Options in Oncology|February 8, 2014
Potential of new therapies like anti-PD1 in kidney cancerAnasuya Gunturi, David F McDermott
Pageof 67

Showing results (51-60 of 666) with videos related to

Sort By:
Pageof 67
Bioscience Reports|June 22, 2017
Effects of microRNA-146a on the proliferation and apoptosis of human osteochondrocytes by targeting TRAF6 through the NF- κB signalling pathwayCamilla West, Michael F McDermott
Genes and Immunity|July 26, 2002
Genetics of type 1 diabetes mellitusF Pociot, M F McDermott
Current Oncology Reports|March 23, 2013
Novel immunotherapies in GU malignanciesAlexandra Drakaki, David F McDermott
The Netherlands Journal of Medicine|October 5, 2001
Hereditary periodic fever syndromesM F McDermott, J Frenkel
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 30, 2018
Progress in Kidney Cancer Outcomes Through Collaboration, Innovation, and DiscoveryDavid F McDermott, Michael Carducci
Expert Opinion on Biological Therapy|August 21, 2018
Ipilimumab in combination with nivolumab for the treatment of renal cell carcinomaXin Gao, David F McDermott
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 21, 2015
Emerging role for novel immunotherapy agents in metastatic renal cell carcinoma: from bench to bedsideMatthew Weinstock, David F McDermott
Current Opinion in Allergy and Clinical Immunology|January 31, 2004
The autoinflammatory syndromesMichael F McDermott, Ivona Aksentijevich
Expert Opinion on Investigational Drugs|December 16, 2014
Nivolumab for the treatment of cancerAnasuya Gunturi, David F McDermott
Current Treatment Options in Oncology|February 8, 2014
Potential of new therapies like anti-PD1 in kidney cancerAnasuya Gunturi, David F McDermott
Pageof 67